Heranova – Lifesciences

logo

about female fertility

Infertility is a common reproductive system disorder that affects millions of couples globally, causing a significant impact on their families and communities. According to research, approximately one in every six individuals of reproductive age around the world experience infertility at some point in their lives.²

IVF (In Vitro Fertilization) can present significant challenges, including the substantial financial burden, the need for time off work for various procedures, and the emotional strain on both the individual undergoing treatment and her loved ones. Additionally, there are health risks associated with IVF, such as potential side effects from medications and an increased likelihood of multiple pregnancies, which carry their own risks, including premature birth and low birth weight.

female infertility
symptoms & causes

Infertility is defined as the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse.7

In the female reproductive system, infertility may be caused by:

  • Tubal disorders such as blocked fallopian tubes, which are in turn caused by untreated sexually transmitted infections (STIs) or complications of unsafe abortion, postpartum sepsis, or abdominal/pelvic surgery
  • Uterine disorders which could be inflammatory  (such as endometriosis), congenital (such as septate uterus), or benign (such as fibroids)
  • Disorders of the ovaries, such as polycystic ovarian  syndrome and other follicular disorders
  • Disorders of the endocrine system which can lead to imbalances in reproductive hormones. The hypothalamus and pituitary glands are part of the endocrine system, and common disorders affecting this system include hypopituitarism and pituitary cancers.

unmet needs presented
by female infertility

While assisted reproduction technologies (ART) have been available for more than three decades, with more than 5 million children born worldwide from ART interventions such as in vitro fertilization (IVF), the overall success rates are still far from satisfactory.

how is Heranova
addressing female fertility?

Heranova™ is currently building a suite of four state-of-the-art tests to provide women with more information and more choices regarding their fertility. These tests are now in the clinical stage:

HerReceptivity™, HerBiota™, HerBiota™—Complete and HerTempo™.

Read more about female infertility
symptoms and causes

Learn about the unmet needs presented by
female infertility

female infertility
symptoms & causes

Infertility is defined as the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse.7

In the female reproductive system, infertility may be caused by:

  • Tubal disorders such as blocked fallopian tubes, which are in turn caused by untreated sexually transmitted infections (STIs) or complications of unsafe abortion, postpartum sepsis, or abdominal/pelvic surgery
  • Uterine disorders which could be inflammatory  (such as endometriosis), congenital (such as septate uterus), or benign (such as fibroids)
  • Disorders of the ovaries, such as polycystic ovarian  syndrome and other follicular disorders
  • Disorders of the endocrine system which can lead to imbalances in reproductive hormones. The hypothalamus and pituitary glands are part of the endocrine system, and common disorders affecting this system include hypopituitarism and pituitary cancers.

unmet needs presented
by female infertility

While assisted reproduction technologies (ART) have been available for more than three decades, with more than 5 million children born worldwide from ART interventions such as in vitro fertilization (IVF)13, the overall success rates are still far from satisfactory.

how is Heranova
addressing female fertility?

Heranova™ is currently building a suite of four state-of-the-art tests to provide women with more information and more choices regarding their fertility. These tests are now in the clinical stage:

HerReceptivity™, HerBiota™, HerBiota™—Complete and HerTempo™.

indication

PRODUCT

 DESCRIPTION

pre-clinical

clinical

launched

Female fertility

HerReceptivityTM

HerReceptivity™ is an NGS-based test to identify each patient’s optimal embryo transplantation time during the IVF process. The average success rate of IVF procedures is currently only ~50% for women under 35 using their own eggs5, and 10% of patients experience recurrent implantation failure caused by repeated IVF failure.6

Endometrial receptivity test

HerBiotaTM

HerBiota™ is an NGS-based test to assess the uterine microbiome environment. It can detect chronic endometritis, and other GYN conditions due to pathogens and/or dysbiosis as well as help clinicians provide personalized treatment recommendations.

Uterine microbiome test

HerBiotaTM
- Complete

HerBiota™-Complete is an NGS-based test to assess both the uterine and vaginal microbiome environment to help clinicians provide personalized treatment recommendations.

Uterine/vaginal microbiome test 

HerTempoTM

HerTempo™ is a proprietary algorithmic-based ovarian reserve assessment for estimating a woman’s remaining childbearing years based on patient-specific clinical information.

Ovarian reserve test

Female fertility

HerReceptivityTM
Endometrial receptivity test

Clinical

HerReceptivity™ is an NGS-based test to identify each patient’s optimal embryo transplantation time during the IVF process. The average success rate of IVF procedures is currently only ~50% for women under 35 using their own eggs5, and 10% of patients experience recurrent implantation failure caused by repeated IVF failure.6

HerBiotaTM
Uterine microbiome test

Clinical

HerBiota™ is an NGS-based test to assess the uterine microbiome environment. It can detect chronic endometritis, and other GYN conditions due to pathogens and/or dysbiosis as well as help clinicians provide personalized treatment recommendations.
HerBiotaTM - Complete
Uterine/vaginal microbiome test 

Clinical

HerBiota™-Complete is an NGS-based test to assess both the uterine and vaginal microbiome environment to help clinicians provide personalized treatment recommendations.

HerTempoTM
Ovarian reserve test

Clinical

HerTempo™ is a proprietary algorithmic-based ovarian reserve assessment for estimating a woman’s remaining childbearing years based on patient-specific clinical information.